Target intelligence / Profile preview

Cytochrome P450 20A1 (CYP20A1)

Target
CYP20A1
Molecular classification
Enzyme, Cytochrome P450 monooxygenase
01

Overview

Cytochrome P450 20A1 (CYP20A1) is an orphan member of the cytochrome P450 enzyme superfamily, found as a single copy gene in vertebrates and classified as the only member of the CYP20 family[2]. Unlike many other cytochrome P450 enzymes, the physiological substrates and catalytic activity of CYP20A1 remain unknown, with no detected activity toward tested steroids, cholesterol, or neurotransmitters in in vitro studies[1][2]. CYP20A1 shows conserved sequence features typical of P450s but also possesses unusual motifs in the I-helix and heme-binding regions, suggesting potentially unique catalytic properties[1]. Its expression has been documented in the brain (notably the hippocampus and substantia nigra), gonads, and during early embryonic development in multiple species, indicating possible functions in neuronal and reproductive biology[1][2]. Loss of CYP20A1 in humans (as part of chromosomal deletions) is associated with neurodevelopmental symptoms such as hyperactivity and anxiety, while animal model knockouts likewise exhibit behavioral phenotypes, supporting a biological role in neurodevelopment and behavior regulation[1][2]. The lack of known interacting drugs or defined biomarkers, as well as absence of established safety profiles, reflect its status as a functionally uncharacterized ("orphan") P450[1][2][3][4].

Other names
Cytochrome P450 family 20 subfamily A member 1cytochrome P450 monooxygenaseCYP-MUNQ667/PRO1301CP20Acytochrome P450, family 20, subfamily A, polypeptide 1
02

Biological functions

Monooxygenase activity (predicted)[3]Heme binding[3]Iron ion binding[3]Putative roles in neuronal function, reproductive function, embryonic development (suggested by expression profiling)[1][2]
03

Disease associations

Neurodevelopmental disorder (implicated by microdeletion studies associating CYP20A1 loss with hyperactivity and anxiety in humans)[2][1]Other (Potential involvement in neurobehavioral toxicity due to environmental agents such as methylmercury)[1]
04

Safety considerations

Unknown endogenous substrate and function, limiting therapeutic or toxicity prediction[1][2]Potential link to neurodevelopmental disorders if disrupted[1][2]

Beyond the preview

Go deeper on Cytochrome P450 20A1 (CYP20A1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cytochrome P450 20A1 (CYP20A1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call